Carson Leslie Foundation #cureMEdullo Team Science Grant in Medulloblastoma
This grant mechanism encourages team science research in childhood medulloblastoma. The purpose of this award is to facilitate collaborations involving a diverse team of investigators, directed toward developing treatment options for childhood medulloblastoma. This is a grant from Carson Leslie Foundation and #cureMEdullo, with Conquer Cancer serving as the lead organization for the review and evaluation of applications and post-award administration.
Purpose
The Carson Leslie Foundation #cureMEdullo Team Science Grant in Medulloblastoma will provide funding to conduct innovative clinical research and emerging treatment strategies leading to better treatments and improved outcomes for medulloblastoma, the most common malignant brain tumor in children.
Brain cancer is the leading cause of cancer death among children, and about 500 children in the United States are diagnosed with medulloblastoma each year. About 20% of childhood brain tumors are medulloblastoma, making it the most common cancerous brain tumor in children but it remains clinically understudied. Thus, there is a need for innovative research and investigators to develop new treatment and care approaches for childhood medulloblastoma patients that would provide fewer long-term side effects including cognitive and physical impairments. This grant mechanism encourages team science research and innovative pilot clinical research ideas to advance the treatment of childhood medulloblastoma. The purpose of this award is to facilitate collaborations involving a diverse team of investigators, directed toward developing novel treatment approaches leading to better treatment options for childhood medulloblastoma. The team is required to have a Principal Investigator who will serve as the Lead PI. This grant also aims to support the development of the next generation of medulloblastoma researchers, and the team is required to include at least one new investigator who will be involved in the research. In addition to the lead PI, the research team can include co-investigators and other key personnel. The role and responsibilities of each team member should be clearly defined.
Funding Available
The total award amount is $100,000 for one year. There is funding for one Carson Leslie Foundation #cureMedullo Team Science Grant in Medulloblastoma which will be awarded to the most meritorious application evaluated for this competition.
Eligibility Criteria
Applicants must meet the following criteria:
- The person indicated as the Lead Principal Investigator (Lead PI) in the grant application is the one who is responsible for the conduct and oversight of the research and who is considered eligible by the sponsor institution to apply as PI for a grant.
- The Lead PI must hold a Doctoral Degree (MD, PhD, MD/PhD, or equivalent), and must hold a full-time faculty appointment at an academic medical or nonprofit research institution within the United States
- The Lead PI has demonstrated ability to carry out the responsibilities of PI.
- The Lead PI must be able to commit at least 60% of full-time effort in research (applies to total research, not just the proposed project) during the award period.
- Other collaborators may serve as Co-Investigators or Key personnel in the project.
- The team must include at least one new investigator, defined as an investigator who has not previously competed successfully for substantial, independent funding from NIH. The new investigator must hold a Doctoral Degree (MD, PhD, MD/PhD, or equivalent). The new investigator must be planning an investigative career in oncology with a focus on childhood medulloblastoma.
Conquer Cancer and the Medulloblastoma Grants Review Committee reserves the right to evaluate and determine an applicant’s eligibility based on the information and justifications included in the application materials. Applicants who are uncertain about their eligibility are encouraged to contact the Grants team for clarification and provide their CV for evaluation.
Application Instructions
The application must be submitted in accordance with the requirements and instructions of the Request for Proposals (RFP) by the application deadline. A Letter of Intent (LOI) is required. All application materials must be in English and must be submitted through the Application Portal. Paper applications or applications sent by e-mail or fax will not be accepted. If you have questions, please email the Grants team.
Key Dates
Online Applications Open: July 11, 2023
Letter of Intent Due: September 29, 2023 (11:59 PM ET)
Letter of Intent Notifications: LOIs will be approved on a rolling basis but no later than September 29, 2023
Full Applications Due: November 6, 2023 (11:59 PM ET)
Anticipated Notification Date: December 2023
Anticipated Award Term: January 1, 2024 – December 31, 2024
EveryGrant®
This grant is administered in collaboration with EveryGrant®, Conquer Cancer, the ASCO Foundation’s, end-to-end, white label solution. EveryGrant® helps organizations develop and deliver grants programs that attract the brightest researchers and make a difference for people with cancer everywhere.